Does Rallies show Form 4 insider transactions for CELC?

Yes. Rallies tracks CELC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CELC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CELC. It does not provide personalized investment advice.

CELC (Celcuity Inc. Common Stock) Stock Analysis - Insider Trades

Celcuity Inc. Common Stock (CELC) is a publicly traded Healthcare sector company. As of May 21, 2026, CELC trades at $138.06 with a market cap of $6.45B and a P/E ratio of -36.79. CELC moved +7.15% today. Year to date, CELC is +35.20%; over the trailing twelve months it is +1217.75%. Its 52-week range spans $7.58 to $151.02. Analyst consensus is strong buy with an average price target of $169.88. Rallies surfaces CELC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CELC stock inside the company?

Recent CELC insider activity includes Dalvey David sold 25.00K, Buller Richard E sold 1.29K, Buller Richard E sold 550, Buller Richard E sold 1.67K, and Buller Richard E sold 2.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CELC Key Metrics

Key financial metrics for CELC
Metric	Value
Price	$138.06
Market Cap	$6.45B
P/E Ratio	-36.79
EPS	$-3.79
Dividend Yield	0.00%
52-Week High	$151.02
52-Week Low	$7.58
Volume	519
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-177.04M
Gross Margin	0.00%

Recent CELC Insider Trades

Dalvey David sold 25.00K (~$3.52M) on May 4, 2026.
Buller Richard E sold 1.29K (~$176.59K) on May 4, 2026.
Buller Richard E sold 550 (~$76.45K) on May 4, 2026.
Buller Richard E sold 1.67K (~$233.10K) on May 4, 2026.
Buller Richard E sold 2.30K (~$324.50K) on May 4, 2026.

Latest CELC News

Celcuity’s Phase 3 Trial Shows PFS Gains, FDA Sets July 17 PDUFA — May 14, 2026
Celcuity Expands VIKTORIA-2 Trial to 1,180 Patients and Files Subcutaneous Patent — May 14, 2026
Celcuity slips after biotech-run surge as traders lock in gains — May 5, 2026
Celcuity surges as Phase 3 VIKTORIA-1 breast-cancer trial hits primary endpoint — May 4, 2026
Celcuity’s Gedatolisib Triplet Yields Clinically Meaningful PFS Boost in PIK3CA Mutant Cohort — May 1, 2026

CELC Analyst Consensus

9 analysts cover CELC: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $169.88.

Common questions about CELC

Who is trading CELC stock inside the company?: Recent CELC insider activity includes Dalvey David sold 25.00K, Buller Richard E sold 1.29K, Buller Richard E sold 550, Buller Richard E sold 1.67K, and Buller Richard E sold 2.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CELC?: Yes. Rallies tracks CELC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CELC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CELC. It does not provide personalized investment advice.